Journal of Cardiovascular Electrophysiology

MARCH 10, 2025

It highlights the confluence of two major cardiovascular epidemics, atrial fibrillation and heart failure, with preserved ejection fraction. ABSTRACT This state-of-the-art review is based on the Philippe Coumel Lecture in 2024 (Figure 1).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Pharmacology 40

The British Journal of Cardiology

APRIL 2, 2025

All services reviewed patients with HF with reduced ejection fraction (HFrEF), only 58% reviewed patients with HF with preserved ejection fraction (HFpEF). Median wait time was 20 days, with substantially longer waits in many areas. All services accepted referrals from multiple sources.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Nursing Pharmacology 40

HeartRhythm

SEPTEMBER 4, 2024

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Quality of Life 40

Journal of Cardiovascular Pharmacology

SEPTEMBER 25, 2024

No abstract available

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure 40

DAIC

APRIL 3, 2024

The “Pharmacology Program” will cover hot topics in cardiovascular medicine that are key issues that pharmacists, as well as other health care team members, face in managing complex patients. This includes a review of updated clinical guidelines and best practices.

Education 105

Education Preserved Ejection Fraction Coronary Artery Disease Cardio Oncology 105

Open Heart

APRIL 24, 2024

We aimed to determine the clinical characteristics which were associated with optimisation of HF pharmacological intervention in the clinic, conducting multivariate regression analysis. HF with preserved ejection fraction (HFpEF) was the most common phenotype and increased significantly compared with the first period (46.3%

Heart Failure 52

Heart Failure Preserved Ejection Fraction ACE Inhibitor Pharmacology 52

Heart BMJ

FEBRUARY 12, 2024

To be familiar with the specific considerations of exercise training prescription in specific HF population groups including HF with preserved ejection fraction. To be aware of needs and requirements of remote delivery (home and digital supported) models of exercise training for people with HF.

Exercise 40

Exercise Heart Failure Preserved Ejection Fraction Pharmacology 40